Home tra

Keywords :   

Tag: tra

TRA approves Viva Bahrain's acquisition of Menatelecom with conditions

2017-10-12 11:02:00| Telecompaper Headlines

(Telecompaper) The Telecommunications Regulatory Authority (TRA) has given approval to Viva Bahrain for its proposed acquisition of Menatelecom, Gulf News reported. TRA said after a process of open consultation and discussions with various parties, it concluded that Viva's plans complied with the necessary regulations. The statement said the TRA first received notification from Viva on 17 August of its proposal to acquire 100 percent of the common equity of Menatelecom.

Tags: conditions tra acquisition viva


Danh mc kim tra HA HON TRONG NH

2016-04-28 01:02:02| PortlandOnline

Home Fire Checklist in Vietnamese PDF Document, 1,133kbCategory: Safety information in foreign languages

Tags: tra kim trong nh


Tanzania: TRA, Police Should Tighten Noose for Fair Sugar Deal

2016-02-24 07:57:13| Sugar Industry News

The government recently announced various measures to control importation of sugar after protracted complaints by different stakeholders including consumers and local producers.

Tags: deal fair police tra


Tata Group, Samsung Mobiles most creative brands: TRA Research Study

2015-11-27 15:30:03| Steel - Topix.net

Salt-to-software conglomerate Tata Group has been ranked as India's most creative brand, according to a TRA Research study. Salt-to-software conglomerate Tata Group has been ranked as India's most creative brand, according to a TRA Research study.

Tags: group research study creative


Two New Post-Hoc Analyses of TRA 2P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease

2015-03-05 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. These and other post-hoc subgroup analyses from TRA-2P are being presented at the 2015 American College of Cardiology Scientific Sessions KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two post-hoc analyses of the TRA 2P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: with added study reduced


Sites : [1] [2] next »